Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

FRAME 001

X
Drug Profile

FRAME 001

Alternative Names: FRAME-001; FRAME-001 personalized vaccine

Latest Information Update: 08 Dec 2022

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Frame Therapeutics
  • Developer CureVac Netherlands
  • Class Antineoplastics; Cancer vaccines; Immunotherapies; Peptide vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No
  • Available For Licensing Yes

Highest Development Phases

  • Phase II Non-small cell lung cancer

Most Recent Events

  • 23 Dec 2021 Frame Therapeutics discontinues a phase II FRAME-001 trial for Non-small cell lung cancer (Second-line therapy or greater) in Netherlands (EudraCT2021-003166-12 )
  • 17 Aug 2021 FRAME 001 is available for licensing as of 17 Aug 2021. https://www.frametherapeutics.com/
  • 10 Aug 2021 Frame Therapeutics plans a phase II trial for Non-small cell lung cancer (Second-line therapy or greater) in Netherlands, in January 2022 (NCT04998474)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top